Roche - GSK - EMILIA: TDM1 ready to take over Tykerb
Today, Roche and ImmunoGen announced the topline data from EMILIA study which met the primary end point of Progression free survival significantly. The study explored the use of Trastuzumab Emtansine (TDM1) against Tykerb and Xeloda in more than 950 patients with HER2 positive metastatic breast cancer whose disease progressed after initial treatment with Herceptin and a taxane based chemotherapy (second line setting). We forecast peak sales of $500m for T-DMI in this indication and this should come at the expense of GSK’s Tykerb, which is the current standard of care in this setting. This is the second study in Herceptin failure patients to demonstrate benefit. Earlier, T-DM1 in two PhII studies, VOGEL and KROP had demonstrated an impressive median PFS of 7.3 m and 4.9 m as a third line treatment option in patients who have failed Tykerb and/or Herceptin and /or chemotherapies.
COMPANIES MENTIONED
ROCHE, GLAXOSMITHKLINE
ROCHE, GLAXOSMITHKLINE
